We profiled a patient with chronic lymphocytic leukemia (CLL) who had a complete and durable response to CAR T cell therapy and found that the CAR construct (which is inserted into the genome by a lentivirus) had disrupted the TET2 locus, rendering it nonfunctional. The gene discussed is TET2; the disease is B-cell chronic lymphocytic leukemia.